References
- De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cuz JJ, Armariao P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57:898–902.
- Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to2008. Circ.2011;124: 1046–1058.
- Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
- Julius S, Kjeldsen SE, Weber M, Brunner H, Ekman S, Hansson L et al. Cardiac events, stroke and mortality in high-risk hypertensives treated with valsartan or amlodipine: Main outcomes of The VALUE Trial. Lancet. 2004;363:2022–31.
- Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet. 2005; 366:895–906.
- Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:2417–28.
- Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Faire U, Fyhrquist F et al. for the LIFE Study Group. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. Am J Hypertens. 2000;13:899–906.
- Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S et al. for the Value Trial. VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens. 2003; 16:544–8.
- Jamerson K, Bakris GL, Dahlöf B, Pitt B, Valesquez E, Gupte J et al. for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Press. 2007, 16:80–86.
- Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR on behalf of the ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): A risk score to identify those at high-risk. J Hypertens. 2011;29: 2004–13.
- de Leeuw PW. Resistance to antihypertensive treatment: Reality or artifact of reasoning? J Hypertens. 2011;29:1861–2.
- Redón J, Coca A, Lázaro P, Aguilar MD, Cabañas M, Gil N, Sánchez-Zamorano MA, Aranda P. Factors associated with therapeutic inertia in hypertension: Validation of a predictive model. J Hypertens. 2010;28:1770–7.
- Schultz M, Aksnes TA, Høieggen A, Kjeldsen SE. Choice of drug in hypertension. Tidsskr Nor Laegeforen. 2013;133: 1802–3. doi: 10.4045/tidsskr.13.0311.
- McInnes GT, Kjeldsen SE. Never mind the quality, feel the width – ALLHAT revisited. Blood Press. 2004;13:330–4.
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med. 2000;342:145–153.
- Modolo R, Faria APD, Sabbatini AR, Moreno H. Resistant hypertension revisited: Definition and true prevalence. J Hypertens. 2014;32:1546.